UNICA IRIS Institutional Research Information System

FARCI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 64.574
NA - Nord America 5.111
AS - Asia 1.708
SA - Sud America 238
AF - Africa 29
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 71.670
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 62.266
US - Stati Uniti d'America 5.070
NL - Olanda 1.063
CN - Cina 811
SG - Singapore 663
UA - Ucraina 456
SE - Svezia 310
BR - Brasile 208
DE - Germania 129
GB - Regno Unito 129
FI - Finlandia 114
KR - Corea 56
VN - Vietnam 53
FR - Francia 36
IN - India 30
CA - Canada 23
HK - Hong Kong 20
RU - Federazione Russa 17
AR - Argentina 13
IR - Iran 13
MX - Messico 11
AT - Austria 10
BD - Bangladesh 9
JP - Giappone 9
IQ - Iraq 8
PK - Pakistan 8
PL - Polonia 8
LT - Lituania 7
ZA - Sudafrica 7
EC - Ecuador 6
EG - Egitto 6
UZ - Uzbekistan 5
EU - Europa 4
GR - Grecia 4
ID - Indonesia 4
MA - Marocco 4
CL - Cile 3
CO - Colombia 3
DK - Danimarca 3
ES - Italia 3
GE - Georgia 3
IE - Irlanda 3
KE - Kenya 3
RO - Romania 3
TH - Thailandia 3
AU - Australia 2
AZ - Azerbaigian 2
BE - Belgio 2
CG - Congo 2
CH - Svizzera 2
KZ - Kazakistan 2
MU - Mauritius 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
TN - Tunisia 2
VE - Venezuela 2
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
FJ - Figi 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
NI - Nicaragua 1
NR - Nauru 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PS - Palestinian Territory 1
PY - Paraguay 1
SA - Arabia Saudita 1
SN - Senegal 1
SV - El Salvador 1
TR - Turchia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 71.670
Salva come PNG Salva come JPEG
Città #
Cagliari 61.295
Amsterdam 1.057
Uta 761
Fairfield 586
Chandler 481
Woodbridge 450
Houston 366
Singapore 362
Ashburn 359
Boardman 256
Ann Arbor 249
Jacksonville 243
Seattle 235
Wilmington 230
Dallas 210
Cambridge 200
Nyköping 180
Beijing 159
Dearborn 123
Hefei 99
Santa Clara 81
Nanjing 70
Boston 69
Los Angeles 68
Buffalo 63
Seoul 56
Shanghai 48
Milan 39
Helsinki 37
San Diego 32
Guangzhou 30
Shenyang 26
Hebei 22
Nanchang 22
New York 22
The Dalles 22
Verona 20
Changsha 19
Hong Kong 18
Redwood City 18
Jiaxing 17
Sassari 17
São Paulo 17
Chicago 16
London 15
Munich 14
Pune 14
Falls Church 13
Tianjin 13
Norwalk 12
Ho Chi Minh City 11
Zhengzhou 11
Hanoi 10
Mountain View 10
Orange 10
Toronto 10
Auburn Hills 9
Guasila 9
Ningbo 9
Renton 9
Rio de Janeiro 9
Tokyo 9
Atlanta 8
Dong Ket 8
Brooklyn 7
Denver 7
Jinan 7
Redmond 7
Redondo Beach 7
Warsaw 7
Washington 7
Belo Horizonte 6
Council Bluffs 6
Kunming 6
Manchester 6
Turku 6
Vienna 6
Brasília 5
Mexico City 5
Orem 5
Phoenix 5
Porto Alegre 5
Rome 5
Tashkent 5
Cairo 4
Chennai 4
Columbus 4
Da Nang 4
Düsseldorf 4
Frankfurt am Main 4
Montreal 4
Nuremberg 4
San Francisco 4
Walnut 4
Augusta 3
Bangkok 3
Campo Grande 3
Catania 3
Chongqing 3
Copenhagen 3
Totale 69.141
Salva come PNG Salva come JPEG
Nome #
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively 2.969
Liver Regeneration Signature in Hepatitis B Virus (HBV)-Associated Acute Liver Failure Identified by Gene Expression Profiling 2.935
Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively 2.741
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis 2.662
Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma. 2.583
Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma 2.514
Association of chronic hepatitis C with recurrent brief depression 2.434
Integrated ordination of miRNA and mRNA expression profiles 2.324
Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue 2.183
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.120
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 1.684
Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure 1.666
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.664
Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma 1.657
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.613
null 1.610
Molecular signature and mechanisms of hepatitis D virus–associated hepatocellular carcinoma 1.480
Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma 1.448
null 1.445
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype 1.424
Clinical Features of Hepatitis D 1.400
Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure 1.355
New Insights into the HCV Quasispecies and Compartmentalization 1.333
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. 1.248
Experimental transmission of hepatitis C virus associated fulminant hepatitis to a chimpanzee 1.244
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. 1.139
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. 1.099
The use of molecular assays in the management of viral hepatitis 852
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. 804
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy 743
Viral escape and the failure of cellular immune responses 665
Treatment of chronic hepatitis D 618
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C 571
Treatment of patients with Chronic Hepatitis Delta 564
Treatment of chronic hepatitis D: New advances, old challenges 533
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin 533
Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B 526
Chronic viral hepatitis D 525
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome 496
In Vivo study of the HC-TN Strain of Hepatitis C Virus Recovered from a Case of Fulminant Hepatitis: RNA Transcripts of a Molecular Clone (pHC-TN) are Infectious in Chimpanzees but not in Huh7.5 cells 492
Natural history and experimental models of hepatitis C 486
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase 486
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies 477
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B 471
Hepatitis D (Delta) Virus 457
Immune Response to Hepatitis C Virus 450
Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection 450
Implicazioni biologiche e cliniche della quasispecie virale 444
The quasispecies of hepatitis C virus and host immune response 435
Clinical relevance of hepatitis C virus genetic variability 429
L’epatite delta 425
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures 423
Lack of protective immunity against reinfection with hepatitis C virus 411
null 399
Hepatitis C virus associated fulminant hepatic failure 398
Long term study of hepatitis C virus replication in non-A non-B hepatitis 390
Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. 387
Evaluation of antibodies to hepatitis C virus in a long-term prospective study of post-transfusion hepatitis among thalassemic children: comparison between first- and second- generation assay 371
Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children 351
Milestones in Liver Disease 342
Delta hepatitis: an update 342
Acute viral hepatitis in Saudi Arabia: seroepidemiological analysis, risk factors, clinical manifestations, and evidence for a sixth hepatitis agent. 340
Virological mechanisms of viral persistence, resolution and reinfection 339
Prevention of hepatitis C virus infection in chimpanzee by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein 337
The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. 333
Peginterferon alfa-2a (40 KD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels 332
Hepatitis C virus. The importance of viral heterogeneity 331
Markers of hepatitis C virus infection in Sardinian blood donors: relationship with alanine aminotransferase levels. 329
Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. 323
La ricerca biomedica 294
HCV-associated lymphomas 292
Prevention of hepatitis C virus infection in chimpanzee after antibody-mediated in vitro neutralization 290
Immunity elicited by hepatitis C virus. 289
Molecular basis of viral resistance to interferon in chronic hepatitis C 288
HCV diversity, dynamics and turnover 285
Clinical significance of hepatitis C virus genotypes and quasispecies 272
Treatment of chronic hepatitis D with interferon alfa-2a 184
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis 182
Totale 71.760
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.485
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.485
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215.294 0 0 0 0 0 1.346 1.195 889 249 744 514 357
2021/20224.003 303 418 235 246 362 341 282 230 261 293 501 531
2022/20235.574 620 696 748 416 541 495 145 860 333 227 240 253
2023/20244.801 397 263 272 453 462 667 534 317 221 398 445 372
2024/20255.331 499 504 778 525 385 456 395 83 196 1.166 148 196
2025/20261.575 256 137 474 246 289 173 0 0 0 0 0 0
Totale 71.760